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Abstract 
 
Heat shock protein (Hsp90) is an ATP dependent chaperone that regulates folding of a wide range 
of client proteins or substrates, which are involved in cellular signaling pathways for tumorigenesis. 
The most of Hsp90 is localized in cytoplasm but mitochondrial Hsp90 homologue, tumor necrosis 
factor receptor-associated protein 1 (TRAP1), has been reported. The TRAP1 is highly elevated in 
many cancer cell types and human cancer patients compared to normal cells. TRAP1 plays 
important roles in tumorigenesis including the neoplastic metabolic shift to aerobic glycolysis, 
tumor cell invasion and metastatasis, inhibition of cell death and development of drug resistance. 
A class of TRAP1 inhibitors, named gamitrinibs (GA mitochondrial matrix inhibitors), has been 
developed through combinatorial chemistry. Gamitrinib consist of geldanamycin, a competitive 
inhibitor of the ATPase pocket of Hsp90 and TRAP1, conjugated with tandem repeats of tetracyclic 
guanidinium or triphenylphosphonium for mitochondrial targeting. Gamitrinib not only trigger 
massive cell death in cultured cancer cells in vitro but also strongly suppress tumor growth in 
various cancer xenograft or genetic mouse model in vivo. The gamitrinib induced cytotoxicity is 
attributed to the reactivation of cyclophilin D (CypD), an opener of the permeability transition pore 
(PTP) located in the mitochondrial inner membrane. PTP opening by CypD activation is often 
suppressed in cancer cells to avoid cell death by interaction with mitochondrial Hsp90s even under 
stressful cellular environment. Furthermore, gamitrinibs have been shown to induce organelle-
specific stress response and dysregulation of bioenergetics in mitochondria of cancer cells. 
Resistance to cell death in the presence of stressful stimuli is one of hallmarks of cancer cells 
acquired during multistep tumorigenesis, and knowledge of the molecular mechanism of stress 
adaptation can be exploited to develop cancer-selective therapeutics. Mitochondria and the 
endoplasmic reticulum (ER) are physically interconnected organelles that can sense and exchange 
various stress signals. Although there have been many studies on stress propagation from the ER to 
mitochondria, reverse stress signals originating from mitochondria have not been well reported. In 
this study, we showed that mitochondrial heat shock protein 90 (Hsp90) suppresses mitochondria-
initiated calcium-mediated stress signals propagating into the ER in cancer cells. Mitochondrial 
Hsp90 inhibition with gamitrinib triggers the calcium signal by opening the mitochondrial 
permeability transition pore and, in turn, the ER ryanodine receptor, via calcium-induced calcium 
release. Subsequent depletion of ER calcium activates unfolded protein responses in the ER, 
thereby increasing the expression of a pro-apoptotic transcription factor, CEBP homologous 
protein (CHOP). Combined treatment of the ER stressor thapsigargin with the mitochondrial 
Hsp90 inhibitor gamitrinib augments interorganelle stress signaling by elevating CHOP expression, 
and showed synergistic cytotoxic activity exclusively in cancer cells in vitro and in vivo. 
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Collectively, the mitochondrial Hsp90s confer apoptosis resistance to cancer cells by suppressing 
the mitochondria-initiated calcium-mediated interorganelle stress response. Next, the mitochondria 
stress inducer, gamibrinib has been exploited, for combination cancer therapy with clinical cancer 
drug doxorubicin (DOX). DOX, an anthracycline antibiotic with the trade name Adrimycin, is one 
of the most effective anticancer drugs and has been widely used to treat cancer patients in various 
combination chemotherapeutic regimens. The antitumor activities of DOX and closely related 
anthracycline analogs are primarily attributed to DNA damage resulting from the inhibition of 
DNA topoisomearse II. DOX has also been reported to increase oxygen derived free radicals, 
which contributes not only to its anticancer activities but also induce a major side effect, 
irreversible cardiomyopathy in the patients. To mitigate the cardiotoxic side effects of DOX, we 
explored the efficacy of combination treatment of DOX with gamitrinib. The combination 
treatment with DOX and gamitrinib showed synergistically increased anticancer activities at 
suboptimal cytotoxic dose in vitro and in vivo, without augmenting the cardiotoxic side effects. The 
mechanism of the action is involved in stimulation of cellular stress signaling mediating JNK of 
CHOP pathways and activation of proapoptotic protein Bim. Depending on cellular context of 
disparate cancer cell types, the combination treatment induced CHOP and Bim expression and 
phosphorylation of JNK and Bim, which leads to enhance accumulation of Bim and Bad in the 
mitochondria. These mechanisms were independent of ROS production and synergistically 
enhanced apoptosis exclusively in cancer cells in vitro and in vivo. In summary, combined 
treatment of TRAP1 inhibitors can unleash the full potential of the anticancer activity of various 
anticancer drugs.
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Chapter 1. Introduction 
 
1-1. Molecular characteristic of chaperones 
1-1-1. Functions of chaperones 
Molecular chaperones are proteins that assist the disassembly or assembly and the unfolding 
or the non-covalent folding of other molecular structures and described first in the literature 
in 1978 [1]. In the cellular biology, proteins are structurally complex and versatile 
macromolecule which are synthesized on ribosome and folded in their native state [2]. 
Generally the chaperones aid in the co-translational folding of newly synthesized proteins 
and helps the conformational change of macromolecules [3]. Some chaperones are linked to 
remodelling of non-native proteins and other chaperones prevent or slow protein aggregation 
or misfolding. Therefore they are essential for protein quality control network [4, 5]. They are 
not highly expressed in normal biological condition. In non-native state as under cellular 
stress, proteins are easy to aggregate by misfolding, unfolding or disassembly. Since the 
chaperones capture misfolded or unfolded polypeptide and stabilize them, they are strongly 
increased to minimize protein aggregation in stressed cells. The chaperones have been 
reported that have function as foldase, holdase and involved in translocation, protein 
degradation, signal transduction, receptor maturation, protein trafficking, immunity and so on 
[6-10]. 
 
1-1-2. Heat shock proteins  
Many chaperones are heat shock proteins because protein folding is severely affected by 
cellular stresses or temperatures [11]. Upon heat shock response, heat shock proteins are 
dramatically increased in transcriptional level by increased Heat shock factor 1 activity [12-
15]. The heat shock proteins (HSP) are named depending on their molecular weight such as 
Hsp40, Hsp60, Hsp70, Hsp90 and Hsp100. Most of HSPs localized in cytosol or ER but 
Hsp60, Hsp70, Hsp90 are also expressed in mitochondria. Hsp100s are ATP dependent 
proteins and capture misfolded proteins and associated in stress tolerance [16]. Hsp90s has 
ATP binding domain and clamp into their client proteins depend on binding ATP [17, 18]. 
Hsp70s are well characterized 70kDa proteins and assisted by Hsp40s. Their client proteins 
are involved in survival factor therefore decreased Hsp70 results in apoptosis [19, 20]. 
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Hsp40s is also called chaperone DnaJ and is the crucial partner of Hsp70 chaperones 
(Table.1) [21-23]. 
 
 
 
1-2. Heat shock protein 90 (Hsp90) 
 
1-2-1 Transcriptional regulation of Hsp90  
Hsp90 is highly abundant in the cytoplasm, where it occupies 1-2% of total protein level 
and its expression about doubles in response to cellular stress in most eukaryotes. Its 
inducible transcription is regulated by the transcription factor heat shock factor1 (HSF1) [12, 
14, 19], which controls approximately hundreds of target genes in response to cellular stress. 
HSF1 is not only a client protein of Hsp90 but also regulated by complex with Hsp90 and 
Hsp70 negatively [19, 24]. HSF1 monomer held in inactive complex with Hsp90 and Hsp70 
but this interaction is broken under cellular stress. Hsp90 capture misfolded protein and other 
client proteins which is increased in stressed cells and HSF1 can be released from Hsp90 
complex (Fig.1) [14, 24]. Therefore, Hsp90 regulates its own transcription [19] . 
 
1-2-2. Cellular location of Hsp90 
Most of Hsp90 is localized in cytoplasm but some Hsp90 is translocated to the nucleus 
under cellular stress [25-27]. Its translocation occurs by co-transport with its client protein 
because Hsp90 has no a nuclear localization sequences. In addition, it found in mitochondria 
in malignant tumour cells and inhibition of Hsp90 function induces apoptosis [28]. 
 
1-2-3. Structure of Hsp90 
Hsp90 is a dimeric protein and very conserved in evolution. Each monomer consists of three 
part such as amino-terminal domain (NTD), middle domain and carboxy- terminal domain 
(CTD). ATP binds in NTD of Hsp90 and hydrolyzed after interaction with Hsp90 and client 
proteins. The Hsp90 middle domain is connected to the NTD by a charged linker and consists 
of two αβα motif. The middle domain is thought to have essential role in client recognition. 
The CTD of Hsp90 has less conserved in sequence than NTD or middle domain and it is 
involved in dimerization. It is mixed α and β domain structurally and end of CTD has the 
tetratricopeptide repeat (TRP) motif recognition site [29]. TRP motif consist of 
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MEEVD( Met-Glue-Glue-Val-Asp) residue and is responsible for interaction with many co-
chaperones [30, 31]. 
 
1-2-4. The function of Hsp90  
In normal cells, Hsp90 plays a many roles including in protein folding, maintenance, 
intracellular transport as well as protein degradation. Generally, Hsp90 suppresses 
aggregation of client protein and helps correct conformational changes. Furthermore, Hsp90 
is needed to keep correct structure of 26s proteosome. The 26s proteosome is involved 
protein degradation for polyubiquitinated proteins so Hsp90 can control protein quality in a 
macro aspects.[32] 
Hsp90 has above 20 client proteins and various cellular functions according to client protein 
such as cellular signal transduction, tumorigenesis, protein trafficking, Heat shock response, 
cell mobility, cell cycle and proliferation and immunity [33-36]. 
 
 
 
1-3. Heat shock protein 90 (Hsp90) homologue proteins 
 
1-3-1. Hsp90 homolgues in other cellular compartments 
In mammalians, Hsp90 family can be divided into 3 sub families: cytosolic Hsp90A, 
endoplasmic reticulum (ER) localized Hsp90B and mitochondrial TNF receptor associated 
protein 1(TRAP1) [37-39]. HSP90A is the most studied of the Hsp90 families and consists of 
two sub-family such as inducible expressed HSP90AA and constitutive expressed HSP90 AB. 
They are abundant in cytosol and some HSP90A can be translocated to nucleus under cellular 
stress. The ER localized HSP90B proteins is also known Grp94 in human and controls in ER 
protein quality [40]. The function of TRAP1 is poorly understood of the other families but 
many papers reported that human TRAP1 protect cells from cellular stress (Fig. 2). 
 
1-3-2. Mitochondrial HSP90 homologue (TRAP1) in cancer 
TRAP1is highly up regulated in cancer cells compared to normal cells and protect cells 
against oxidative stress and apoptosis [41, 42]. This pathway is involved in mitochondrial 
permeability transition (MPT). TRAP1 binds to cyclopphilin D (CypD) which is key 
molecule in permeability transition (PT) pore complex and their interaction results to 
inactive CypD so blocked PT pore opening [43]. In addition, TRAP1 may play a role in 
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organelle homeostasis by involving protein folding quality control [44]. TRAP1 preserve 
Hexokinase II (HK II) and stability of succinate dehydrogenase (SDHB) [45-48]. HK II is a 
key mediator of glycolysis and SDHB is associated with oxidative phosphorylation. Both of 
enzymes play important roles in cellular homeostasis and metabolic network. Inhibition of 
TRAP1 by genetically or pharmacologically impairs both oxidative phosphoryalation and 
glycolysis. The TRAP1 has a quite different cellular functions and client proteins from the 
cytosolic Hsp90 protein. Through reprogramming cancer cell metabolism, TRAP1 are 
involved in cytoprotection, tumour progression and multidrug resistance [46-48]. 
 
1-3-3. Inhibitors against TRAP1 
A class of mitochondrotropic Hsp90 inhibitors, named gamitrinibs (GA mitochondrial 
matrix inhibitors), has been developed through combinatorial chemistry. Gamitrinib consist 
of geldanamycin, a competitive inhibitor of the ATPase pocket of Hsp90 and TRAP1, 
conjugated with tandem repeats of tetracyclic guanidinium or triphenylphosphonium for 
mitochondrial targeting (Fig.3). Gamitrinib not only trigger massive cell death in cultured 
cancer cells in vitro but also strongly suppress tumor growth in various cancer xenograft or 
genetic mouse model in vivo. The gamitrinib induced cytotoxicity is attributed to the 
reactivation of cyclophilin D (cypD), an opener of the permeability transition pore (PTP) 
located in the mitochondrial inner membrane. CypD inactivation is often suppressed in 
cancer cells by interaction with mitochondrial Hsp90s because the opening of the PTP can be 
lethal. Furthermore, gamitrinibs have been shown to induce organelle-specific stress 
response and dysregulation of bioenergetics in mitochondria of cancer cells (Fig.4) [49-52]. 
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HSPs family Cellular location Functions 
Small Hsps cytosol Heat inactivation, Suppress aggregation 
Hsp40 Cytosol Crucial co-chaperone activity with Hsp70 
Hsp60 
Mitochondria 
Cytosol 
Refold and prevent aggregation 
Hsp70 
ER, mitochondria 
Cytosol 
Interorganellar transport, 
Antiapoptotic activity 
Autoregulation of the heat shock response 
Hsp90 ER, cytosol 
Signal transduction i cell cycle and 
proliferation 
Refold and regulation client protein 
Protein trafficking 
Hsp100 cytosol Control stress tolerance 
 
 
Table 1-1. Family of Heat shock proteins and their functions 
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family Subcelluar location type 
HSP90A (Hsp90a) Cytosol 
Hsp90AA (inducible) 
Hsp90AB (constitutive) 
HSPB (Hsp90b, Grp94) ER  
TRAP1 mitochondria  
 
 
Table 1-2. Family of Heat shock protein 90 (Hsp90) 
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Figure 1-1. HSF1 activation and attenuation cycle [24] 
             Nature Reviews Drug Discovery 10, 930-944 
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Figure 1-2. Hsp90 homologue proteins 
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Figure 1-3. The structure of Gamitrinib 
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Figure 1-4. Hsp90 and TRAP1 regulates tumour cell survival [43] 
Nature Medicine 13, 1415 - 1417 (2007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
1-4. References 
 
1. Ellis, R.J., Discovery of molecular chaperones. Cell Stress Chaperones, 1996. 1(3): p. 
155-60. 
2. Richardson, R.T., et al., Nuclear autoantigenic sperm protein (NASP), a linker histone 
chaperone that is required for cell proliferation. J Biol Chem, 2006. 281(30): p. 21526-
34. 
3. Ellis, R.J., Molecular chaperones: assisting assembly in addition to folding. Trends 
Biochem Sci, 2006. 31(7): p. 395-401. 
4. Ellis, R.J., Protein misassembly: macromolecular crowding and molecular chaperones. 
Adv Exp Med Biol, 2007. 594: p. 1-13. 
5. Fenton, W.A. and A.L. Horwich, Chaperonin-mediated protein folding: fate of substrate 
polypeptide. Q Rev Biophys, 2003. 36(2): p. 229-56. 
6. Hoffmann, J.H., et al., Identification of a redox-regulated chaperone network. EMBO J, 
2004. 23(1): p. 160-8. 
7. DeFranco, D.B., C. Ramakrishnan, and Y. Tang, Molecular chaperones and subcellular 
trafficking of steroid receptors. J Steroid Biochem Mol Biol, 1998. 65(1-6): p. 51-8. 
8. Brown, M.A., et al., Hsp90--from signal transduction to cell transformation. Biochem 
Biophys Res Commun, 2007. 363(2): p. 241-6. 
9. Richter, K. and J. Buchner, Hsp90: chaperoning signal transduction. J Cell Physiol, 
2001. 188(3): p. 281-90. 
10. Pratt, W.B., The hsp90-based chaperone system: involvement in signal transduction 
from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med, 1998. 
217(4): p. 420-34. 
11. Ellis, R.J. and S.M. van der Vies, Molecular chaperones. Annu Rev Biochem, 1991. 60: 
p. 321-47. 
12. Zou, J., et al., Repression of heat shock transcription factor HSF1 activation by HSP90 
(HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell, 1998. 94(4): p. 
471-80. 
13. Wang, X., et al., Phosphorylation of HSF1 by MAPK-activated protein kinase 2 on 
serine 121, inhibits transcriptional activity and promotes HSP90 binding. J Biol Chem, 
2006. 281(2): p. 782-91. 
14. Marunouchi, T., et al., Possible involvement of HSP90-HSF1 multichaperone complex 
in impairment of HSP72 induction in the failing heart following myocardial infarction 
19 
 
in rats. J Pharmacol Sci, 2013. 123(4): p. 336-46. 
15. Donnelly, N., et al., HSF1 deficiency and impaired HSP90-dependent protein folding 
are hallmarks of aneuploid human cells. EMBO J, 2014. 33(20): p. 2374-87. 
16. Zeymer, C., et al., The molecular mechanism of Hsp100 chaperone inhibition by the 
prion curing agent guanidinium chloride. J Biol Chem, 2013. 288(10): p. 7065-76. 
17. Niknejad, H., et al., Inhibition of HSP90 could be possible mechanism for anti-cancer 
property of amniotic membrane. Med Hypotheses, 2013. 81(5): p. 862-5. 
18. Hostein, I., et al., Inhibition of signal transduction by the Hsp90 inhibitor 17-
allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res, 
2001. 61(10): p. 4003-9. 
19. Nakamura, M., et al., Expression of hsp70, hsp90 and hsf1 in the reef coral Acropora 
digitifera under prospective acidified conditions over the next several decades. Biol 
Open, 2012. 1(2): p. 75-81. 
20. Aghdassi, A., et al., Heat shock protein 70 increases tumorigenicity and inhibits 
apoptosis in pancreatic adenocarcinoma. Cancer Research, 2007. 67(2): p. 616-625. 
21. Shukla, H.D. and B.R. Singh, Identification of a 40 kDa heat shock protein in 
Clostridium botulinum type A as DnaJ like chaperone. Abstracts of Papers of the 
American Chemical Society, 1998. 216: p. U561-U561. 
22. Bustard, K. and R.S. Gupta, The sequences of heat shock protein 40 (DnaJ) homologs 
provide evidence for a close evolutionary relationship between the Deinococcus-
Thermus group and cyanobacteria. Journal of Molecular Evolution, 1997. 45(2): p. 
193-205. 
23. Cuellar, J., et al., Structural Insights into the Chaperone Activity of the 40-kDa Heat 
Shock Protein DnaJ BINDING AND REMODELING OF A NATIVE SUBSTRATE. 
Journal of Biological Chemistry, 2013. 288(21): p. 15065-15074. 
24. Neef, D.W., A.M. Jaeger, and D.J. Thiele, Heat shock transcription factor 1 as a 
therapeutic target in neurodegenerative diseases. Nature Reviews Drug Discovery, 
2011. 10(12): p. 930-944. 
25. Gallo, L.I., et al., The 90-kDa heat-shock protein (Hsp90)-binding immunophilin 
FKBP51 is a mitochondrial protein that translocates to the nucleus to protect cells 
against oxidative stress. J Biol Chem, 2011. 286(34): p. 30152-60. 
26. Suetsugu, S. and T. Takenawa, Translocation of N-WASP by nuclear localization and 
export signals into the nucleus modulates expression of HSP90. J Biol Chem, 2003. 
278(43): p. 42515-23. 
20 
 
27. Galigniana, M.D., et al., Hsp90-binding immunophilins link p53 to dynein during p53 
transport to the nucleus. J Biol Chem, 2004. 279(21): p. 22483-9. 
28. Vanden Berghe, T., et al., Disruption of HSP90 function reverts tumor necrosis factor-
induced necrosis to apoptosis. J Biol Chem, 2003. 278(8): p. 5622-9. 
29. Didenko, T., et al., Hsp90 structure and function studied by NMR spectroscopy. 
Biochim Biophys Acta, 2012. 1823(3): p. 636-47. 
30. Pearl, L.H. and C. Prodromou, Structure and mechanism of the Hsp90 molecular 
chaperone machinery. Annu Rev Biochem, 2006. 75: p. 271-94. 
31. Li, J. and J. Buchner, Structure, function and regulation of the hsp90 machinery. 
Biomed J, 2013. 36(3): p. 106-17. 
32. Nathan, D.F. and S. Lindquist, Mutational analysis of Hsp90 function: interactions with 
a steroid receptor and a protein kinase. Mol Cell Biol, 1995. 15(7): p. 3917-25. 
33. Pratt, W.B. and D.O. Toft, Regulation of signaling protein function and trafficking by 
the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood), 2003. 228(2): 
p. 111-33. 
34. Bagatell, R. and L. Whitesell, Altered Hsp90 function in cancer: a unique therapeutic 
opportunity. Mol Cancer Ther, 2004. 3(8): p. 1021-30. 
35. McClellan, A.J., et al., Diverse cellular functions of the Hsp90 molecular chaperone 
uncovered using systems approaches. Cell, 2007. 131(1): p. 121-35. 
36. Liu, Y., et al., Molecular chaperone Hsp90 associates with resistance protein N and its 
signaling proteins SGT1 and Rar1 to modulate an innate immune response in plants. J 
Biol Chem, 2004. 279(3): p. 2101-8. 
37. Altieri, D.C., et al., TRAP-1, the mitochondrial Hsp90. Biochim Biophys Acta, 2012. 
1823(3): p. 767-73. 
38. Chen, B., et al., The HSP90 family of genes in the human genome: insights into their 
divergence and evolution. Genomics, 2005. 86(6): p. 627-37. 
39. Chen, B., et al., The expression of the HSP90 gene in response to winter and summer 
diapauses and thermal-stress in the onion maggot, Delia antiqua. Insect Mol Biol, 2005. 
14(6): p. 697-702. 
40. Marzec, M., D. Eletto, and Y. Argon, GRP94: An HSP90-like protein specialized for 
protein folding and quality control in the endoplasmic reticulum. Biochim Biophys Acta, 
2012. 1823(3): p. 774-87. 
41. Kang, B.H., TRAP1 regulation of mitochondrial life or death decision in cancer cells 
and mitochondria-targeted TRAP1 inhibitors. BMB Rep, 2012. 45(1): p. 1-6. 
21 
 
42. Kang, B.H., et al., Regulation of tumor cell mitochondrial homeostasis by an organelle-
specific Hsp90 chaperone network. Cell, 2007. 131(2): p. 257-70. 
43. Workman, P. and E. de Billy, Putting the heat on cancer. Nat Med, 2007. 13(12): p. 
1415-7. 
44. Nakagawa, T., et al., Cyclophilin D-dependent mitochondrial permeability transition 
regulates some necrotic but not apoptotic cell death. Nature, 2005. 434(7033): p. 652-8. 
45. Chae, Y.C., et al., Control of tumor bioenergetics and survival stress signaling by 
mitochondrial HSP90s. Cancer Cell, 2012. 22(3): p. 331-44. 
46. Siegelin, M.D., et al., Exploiting the mitochondrial unfolded protein response for 
cancer therapy in mice and human cells. J Clin Invest, 2011. 121(4): p. 1349-60. 
47. Chae, Y.C., et al., Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat 
Commun, 2013. 4: p. 2139. 
48. Boland, M.L., A.H. Chourasia, and K.F. Macleod, Mitochondrial dysfunction in cancer. 
Front Oncol, 2013. 3: p. 292. 
49. Kang, B.H., et al., Preclinical characterization of mitochondria-targeted small molecule 
hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res, 2010. 
16(19): p. 4779-88. 
50. Kang, Y.J., et al., Inhibition of doxorubicin chronic toxicity in catalase-overexpressing 
transgenic mouse hearts. Chem Res Toxicol, 2002. 15(1): p. 1-6. 
51. Kang, B.H., et al., Combinatorial drug design targeting multiple cancer signaling 
networks controlled by mitochondrial Hsp90. J Clin Invest, 2009. 119(3): p. 454-64. 
52. Yoshida, S., et al., Molecular chaperone TRAP1 regulates a metabolic switch between 
mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci U S A, 2013. 
110(17): p. E1604-12. 
 
 
 
22 
 
Chapter 2. Mitochondrial Hsp90s suppress calcium-mediated stress 
signals propagating from mitochondria to the ER in cancer cells 
 
2-1. Introduction 
 
Molecular chaperones help the conformational changes and correct folding of their substrates, 
called client proteins, and minimize their aggregation and misfolding [1]. Heat shock protein 90 
(Hsp90) is an ATP-dependent molecular chaperone which regulates the function and the 
stability of client proteins which are associated with signal transduction during malignant 
transformation and progression [2, 3]. Organelle-resident Hsp90 family proteins are mainly 
expressed in the endoplasmic reticulum(ER) and mitochondria, where they control protein 
homeostasis [4, 5]. The mitochondrial Hsp90s, tumor necrosis factor receptor-associated protein 
1 (TRAP1), are abundant in the mitochondria of many cancer cells [6, 7], and their client 
proteins, cellular functions and regulation are quite different from the cytoplasmic Hsp90 pool 
[4, 6]. TRAP1 are involved in cytoprotection, tumor progression, and multidrug resistance by 
reprogramming metabolic network of cancer cell [8-12] and sustaining mitochondrial membrane 
integrity [6, 13, 14]. Mitochondria integrate vital and lethal signals emanating from various 
cellular compartments to bring about cell death through inner and outer membrane 
permeabilization [15]. Although the molecular mechanism is not clear, cyclophilin D (Cyp-D) is 
reported to regulate the permeability transition pore (PTP) in the mitochondrial inner membrane 
[16-20]. TRAP1 expression is elevated in cancer cells, which suppresses Cyp-D function to 
suppress the deadly increase of membrane permeability in the organelle [6]. PTP opening upon 
Cyp-D activation increases mitochondrial inner membrane permeability toward small molecules 
(<1,500 Da), resulting in loss of mitochondrial membrane potential (ΔΨm), discharge of matrix 
calcium stores, and swelling and rupture of the mitochondrial outer membrane [15, 21]. 
Calcium, a ubiquitous second messenger, is associated in a broad variety of physiological events 
via its interaction with effectors responsible for calcium-dependent processes [22]. The 
mitochondria and ER are the major intracellular calcium stores, regulating calcium signaling 
and homeostasis [23, 24]. They have a largely interconnected architecture with numerous 
contacts, which facilitates inter-organelle calcium transport by generating calcium hotspots 
proximal to open calcium channels [25-27]. Both the ER and mitochondria contain calcium-
triggered calcium release channels that can activate each other via positive feedback, including 
ryanodine receptors (RyRs) and inositol 1,4,5-trisphosphate receptors (IP3Rs) [15, 28]. There is 
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a growing consensus that ER-mitochondria calcium crosstalk can coordinate signaling for 
metabolism and cell death between the organelles [24]. Although calcium signaling has been 
intensively studied, reports of “mitochondria-initiated” calcium crosstalk between mitochondria 
and the ER are scarce. Here, we demonstrate a novel function of mitochondrial Hsp90s that 
confers resistance to cancer cell death by inhibiting the propagation of mitochondrial-origin 
calcium signals to the ER. 
 
 
 
2-2. Materials and methods 
 
Cells and culture condition 
HeLa, MDA-MB-231, and NCI-H460 cells were purchased from the Korean Cell Line Bank 
and 22Rv1 from the American Type Culture Collection. Cell lines were maintained as 
recommended by supplier. Cells were cultured in DMEM or RPMI medium (Lonza) containing 
10% fetal bovine serum (FBS; GIBCO) and 1% penicillin/streptomycin (GIBCO) at 37°C in a 
5% CO2 humidified atmosphere. 
 
Chemicals, plasmids and antibodies 
Gamitrinib conjugated with triphenylphosphonium was prepared as described previously[29].  
MitoTracker, Fura-2-AM, and tetramethylrhodamine methyl ester (TMRM) were purchased 
from Molecular Probes, Ryanodine was from Santa Cruz Biotechnology. Mn(III) tetrakis 
(1-methyl-4-pyridyl) porphyrin (MnTMPyP) was from Calbiochem. 1,2-bis(o-aminophenoxy) 
ethane-N,N,N’,N’-tetraacetic acid acetoxymethyl ester (BAPTA), cyclosporine A (CsA), 
carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), tetracaine, and 
thapsigargin(Thap), and N-acetylcysteine (NAC) and all other chemicals were from Sigma, 
Anti-CEBP homologous protein (CHOP) antibodies were obtained from Cell Signaling; anti-
RyR, anti-IP3R,anti-eIF2α and anti-cytochrome c antibodies from Santa Cruz Biotechnology; 
anti-cyclopholin D from Calbiochem; anti-eIF2α[pS52] from Invitrogen; anti-β-actin from MP 
Biomedicals; and anti-TRAP1 from BD Biosciences. 
 
Astrocyte preparation 
Primary cultures of astrocytes were prepared as previously described[30]. Briefly, the mouse 
brain cortex, after removing the meninges, was dissected and dissociated with moderate 
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pipetting. Cells were plated on 100-mm dishes coated with 10 μg/ml poly-D-lysine (Sigma) and 
grown to confluence in DMEM supplemented with 10% FBS, 10% horse serum (GIBCO), 100 
units/ml penicillin, and 100 μg/ml streptomycin at 37°C in a 5% CO2 humidified atmosphere. 
Afterward, astrocytes were trypsinized and plated on 6-well plates coated with poly-D-lysine to 
administer drugs. 
 
siRNA treatment 
Small interfering RNAs (siRNA) against TRAP1, RyR2, IP3R, and CHOP were synthesized by 
Genolution (Korea) as follows:  
RyR2-#1, 5′-AAGTGGTTCTGCAGTGCACCG; RyR2-#2,5′-AAGTACGAGTTGGAGATG 
ACC; TRAP1-#1, 5′- AAACATGAGTTCCAGGCCGAG;TRAP1-#2, 5′- CCCGGTCCCTGT 
ACTCAGAAA; IP3R1-#1, 5′-GAGAATTTCCTTGTAGACATCTGCA; IP3R1-#2, 5′-GGCC 
TGAGAGTTACGTGGCAGAAAT; IP3R2, 5′-GAGAAGGCTCGATGCTGAGACTTGA; 
IP3R3, 5′-CCGAGATGACAAGAAGAACAAGTTT;CHOP-#1, 5′-AGAACCAGCAGAGG 
TCACAA;CHOP-#2,5′-AAGAGAATGAACGGCTCAAGC; control, 5′-ACUCUAUCUGCA 
CGCUGAC.  
 
Cells were cultured on 6-well plates at 50–75% confluence, transfected with 20 nM siRNA 
mixed with G-Fectin (Genolution) for 48 hours, and then analyzed or treated with drugs. 
Analysis of cell viability and apoptosis induction Cells (5 × 103 cells/well) were cultured in 96-
well plates overnight and treated with gamitrinib and Thap alone or in combination for 24 hours. 
To determine cell viability, cells were exposed to 3 (4,5-dimethyl-thyzoyl-2-yl)2,5 
diphenyltetrazolium bromide (MTT), and crystallized formazan was quantified by measuring 
the absorbance at 595 nm with an Infinity M200 microplate reader (TECAN). Absorbance data 
were compared with that of vehicle control and expressed as percent viability. Alternatively, 
after treatment with drugs, DNA content (propidiumiodide, red fluorescence) and caspase 
activation (DEVDase activity, green fluorescence) of the cells were analyzed using the 
CaspaTag in situ apoptosis detection kit (Millipore). Labeled cells were analyzed using the 
FACS Calibur™ system (BD Biosciences). Data were processed using FlowJo software 
(TreeStar). 
 
CHOP reporter assay 
To generate a CHOP reporter stable cell line, PC 3 cells were co-transfected with 8 μg of a 
promoter construct (CHOP::GFP)[31] obtained from Addgene (Addgene plasmid 21898) and 
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800 ng of puromycin linearized selection marker (Clontech) using Lipofectamin (Invitrogen) 
per manufacturer’s instructions. Transfected PC3 cells were cultured in RPMI (Lonza) with 1 
μg/ml puromycin (Clontech) for 3 weeks and colonies were picked using cloning cylinders. 
GFP expression was monitored in the IncuCyte™ imaging system (Essen Bioscience) at an 
excitation wavelength of 450–490 nm and an emission of 500–530 nm, and analyzed by Image J 
software (National Institutes of Health).  
 
Live cell imaging for intracellular calcium 
HeLa cells were incubated with 5 μM Fura-2-AM for 30 min at 37°C and 5% CO2. After 
washing with Hank’s Buffer, the cells were incubated with calcium-free Locke’s solution (154 
mM NaCl, 5.6 mM KCl, 3.2 mM MgCl2, 5 mM HEPES, 10 mM glucose, 0.2 mM EGTA; pH 
7.4). Fluorescence changes were monitored every 5 minutes using an IX81 ZDC microscope 
(Olympus) at an emission wavelength of 510 nm with dual excitation at 340 nm and 380 nm. 
Images of the 340/380 fluorescence ratio were generated and analyzed by the Xcellence 
software package (Olympus). Imaging D1ER and mtCameleon Fluorescence resonance energy 
transfer (FRET) measurements were performed using an FV1000 laser confocal scanning 
microsope (Olympus) with a FRET module and a UPLSAPO 100× oil immersion objective with 
a 1.40 numerical aperture. HeLa cells were seeded on a Lab Tek II slide chamber at 40–80% 
confluency in DMEM (Lonza) supplemented with 10% FBS and 1% penicillin/streptomycin at 
37°C and 5% CO2. D1ER or mtCameleon constructs (kind gifts from Dr. R.Y. Tsien, University 
of San Diego) [32] were transfected into HeLa cells using the Lipofectamine transfection 
reagent (Invitrogen) per manufacturer’s instructions. Cells were imaged at 24 or 48 hours after 
transfection. All analyses were performed under the same conditions. D1ER and mtCameleon, 
containing FRET donor (CFP) and acceptor (citrine) components, were excited with a 440-nm 
diode laser source; the emitted fluorescence bands were separated by a grating and detected by 
photomultiplier tubes in the CFP channel (480 nm) and FRET channel (535 nm). The FRET 
ratio (RFRET) was calculated as described previously[33] from confocal images using FV10-
ASW 3.1 software (Olympus) by pixel-by-pixel quantification of fluorescence intensity: 
RFRET = IFRET/ICFP, where IFRET and ICFP represent the fluorescence intensities from the 
FRET and CFP channels, respectively. The FRET ratio (relative units) was plotted after 
comparing RFRET values. 
 
RNA extraction and reverse transcript-PCR 
Total RNA was prepared from cells suspended in cold PBS using the RNeasy mini kit 
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(QIAGEN), and cDNA was synthesized using the ProtoScript®  First Strand cDNA Synthesis 
Kit (New England Biolabs) using an oligo(dT) primer. The PCR reaction was performed in a 
Mastercycler PCR machine (Eppendorf) with the following sets of oligonucleotide primers: 
glyceraldehyde phosphate dehydrogenase (GAPDH), 5′-CGGGAAGCTTGTCATCAATGG-3′ 
and 5′-GGCAGTGATGGCATGGACTG-3′; CHOP, 5′- CTTTCTCCTTCGGGACACTG-3′ and 
5′-AGCCGTTCATTCTCTTCAGC-3′; TRAP1, 5′-ATGGCGCGCGAGCTGCGG-3′ and 5′-
CAGTCGTCCTGCCTGCAA-3′; X-box binding protein 1 (XBP1), 5′-CCTTGTAGTTGAGAA 
CCAGG-3′ and 5′-GGGGCTTGGTATATATGTGG-3′. 
 
Xenograft tumor models 
All experiments involving animals were approved by UNIST (IACUC-12-003-A). 22Rv1 (7 × 
106) cells suspended in sterile PBS (200 μl) were injected subcutaneously into both flanks of 6-
week-old BALB/c nu/nu male mice (Japan SLC Inc.) and allowed to grow to an average volume 
of approximately 100 mm3. Animals were randomly divided into four groups (two 
tumors/mouse, five mice/group). Gamitrinib or vehicle (DMSO) dissolved in 20% Cremophor 
EL (Sigma) in PBS was injected intraperitoneally, and Thap dissolved in 0.9% NaCl in PBS 
intravenously. The mice were administered 10 mg/kg gamitrinib and 0.2 mg/kg Thap twice a 
week. Tumors were measured daily with a caliper, and tumor volume was calculated using the 
formula: V = 1/2 × (width)2 × length. At the end of experiment, animals were euthanized, and 
organs including brain, heart, kidney, liver, lung, spleen, and tumor were collected for histology 
or western blotting. For histological analysis, harvested organs were fixed in 10% formalin and 
embedded in paraffin. Sections (5 μm) were placed on high-adhesive slides, stained with H&E, 
and scanned using the Dotslide system (Olympus) with 10× magnification. For western blot 
analysis, tissue samples were lysed in RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-
40, and 0.25% N-deoxycholate) containing protease inhibitor and phosphatase inhibitor 
cocktails (Calbiochem) using a homogenizer (IKA). 
 
Statistical analysis of data 
All MTT experiments were duplicated and repeated independently at least three times. 
Statistical analyses were performed using the software program Prism 5.0 (GraphPad). In an 
unpaired t-test, p < 0.05 was considered significant. 
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2-3. Results 
 
Mitochondrial Hsp90s regulate the mitochondrial calcium store 
To investigate whether mitochondrial Hsp90s regulate mitochondrial calcium stores, we used 
the mitochondriatargeted Hsp90 inhibitor gamitrinib, a conjugated of triphenylphosphonium (a 
mitochondria-targeting moiety) and geldanamycin (an Hsp90 inhibitor) [29, 34]. A cytotoxic 
dose (30 μM) of gamitrinib dramatically increased the intracellular calcium concentration 
within an hour in human cervical (HeLa), prostate (22Rv1), and breast (MDA-MB-231) cancer 
cell lines in calcium-free medium (Fig. 2-1A and B). A non-targeted Hsp90 inhibitor, 17-
allylamino-17-demethoxygeldanamycin (17AAG), did not increase cytosolic calcium (Fig. 2-
1D), consistent with a previous report that gamitrinib is specific to mitochondrial Hsp90 
without affecting cytosolic Hsp90 function [29]. After gamitrinib treatment, PTP opening and 
loss of mitochondrial membrane potential (ΔΨm) occurred within 30 minutes (Fig. 2-2A, 
TMRM staining), whereas cytochrome c release (Fig. 2-2B, cytochrome c staining) were not 
prominent until after 2 hours. Caspase activation and cell death occured after 4 hours (Fig. 2- 
1C, DEVDase activity and PI staining), and it suggested that calcium flux concurs with PTP 
opening, prior to mitochondrial outer membrane permeabilization (MOMP). Consistently, 
cytosolic calcium elevation was inhibited by cyclosporin A (CsA) (Fig. 2-1C), a potent Cyp-D 
inhibitor, blocking PTP opening [15]. Thus, mitochondrial Hsp90 inhibition immediately 
induces PTP opening, loss of ΔΨm, and discharge of the calcium stored in the mitochondrial 
matrix. Thereafter, a cascade of MOMP, cytochrome c release, and caspase activation ensues 
(Fig. 2-2D). 
 
Mitochondrial calcium release results in depletion of ER calcium 
The PTP opening has been shown to immediately discharge calcium stored in the mitochondria 
[35]; however, after mitochondrial Hsp90 inhibition in this study, calcium release continued 
even after a significant drop in ΔΨm (Fig. 2-1A and 2-2A), suggestive of additional sources of 
calcium flux. We postulated that the primary calcium-storing organelle, the ER, contributes to 
the cytosolic calcium increase after gamitrinib treatment. To prove this, we directly measured 
calcium depletion using the calcium sensor protein, Cameleon, targeted to mitochondria and the 
ER (mtCameleon and D1ER, respectively) [32]. Gamitrinib treatment resulted in FRET signal 
loss in both mtCameleon- and D1ER-transfected HeLa cells, comparable to that seen with 
FCCP or Thap treatment (Fig. 2-3A and B), clearly indicating calcium depletion in the ER as 
well as in mitochondria. FCCP is used to observe as positive control which can affect 
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mitochondria specifically and Thapsigargin is used to release stored Calcium as an inhibitor of 
the Ca
2+
 -ATPase of the ER (Fig. 2-3C and D). Consistent with previous reports [29], the non-
targeted Hsp90 inhibitor 17AAG did not affect the mtCameleon FRET signal (Fig. 2-4A and B) 
and gamitrinib has no effect on the ΔΨm of a normal MCF10A breast cell (Fig. 2-5A and B).  
Calcium depletion in the ER evokes the unfolded protein response and induces CHOP activation 
Gamitrinib has been reported to trigger the unfolded protein response in mitochondria, and, 
through unknown mechanisms, to subsequently activate CHOP, the proapoptotic transcription 
factor often induced during unfolded protein responses in the ER (UPRER) [4, 36-38]. siRNA 
knockdown of the mitochondrial Hsp90 homolog TRAP1 results in spliced XBP1 mRNA 
production and eukaryotic translation initiation factor 2α (eIF2α) phosphorylation (Fig. 2-6A 
and B), suggesting activation of UPRER sensor proteins such as inositol-requiring protein1α 
(IRE1α) and PKR-like ER kinase[39, 40]. Consistently, pharmacological inactivation of 
mitochondrial Hsp90s by gamitrinib also triggered eIF2α phosphorylation and XBP1mRNA 
splicing (Fig. 2-6C and 2-7). In addition to UPRER sensor protein activation, CHOP induction 
was clearly seen after both pharmacological and genetic inhibition of mitochondrial chaperones 
(Fig. 2-6D). To investigate the critical involvement of mitochondrial calcium discharge through 
the PTP for the ER stress response, gamitrinib was administered in the presence or absence of 
the PTP inhibitor CsA and the calcium chelator BAPTA. Both substances compromised UPRER 
induction, resulting in a dramatic reduction in eIF2α phosphorylation and CHOP expression 
(Fig. 2-7). 
 
Ryanodine receptors mediate mitochondrial calcium-induced calcium depletion in the ER 
IP3Rs and RyRs are ER membrane channels responsible for calcium release from the organelle 
[22]. Silencing IP3R1, the major isoform in HeLa cells [41] (Fig. 2-8A), did not affect the 
elevation of cytosolic calcium and the induction of CHOP after gamitrinib treatment (Fig. 2-8B 
and C), but was enough to compromise lysophosphatidic acid-induced ER calcium release in 
calcium-free medium (Fig. 2-8D). By contrast, specific RyR inhibitors such as ryanodine (100 
μM) and tetracaine (300 μM)[42] strongly inhibited gamitrinib-induced ER calcium release, 
similar to the PTP inhibitor CsA (Fig. 2-9A). Genetic knockdown of RyR2 the dominant RyR 
isoform in HeLa cells [43-45], also blocked gamitrinib-induced cytoplasmic calcium increase 
(Fig. 2-9B and C). Consistently, ryanodine and RyR2-specific siRNAs inhibited eIF2α 
phosphorylation and the subsequent CHOP induction (Fig. 2-9B and D). Collectively, our data 
suggest that RyR, not IP3R, is the ER sensor that propagates the signal initiated by discharged 
calcium from mitochondria in cancer cells. Although Reactive oxygen species (ROS) has known 
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as a factor to release ER calcium but ROS did not affect gamitrinib-induced calcium release and 
CHOP induction in this mechanism (Fig. 2-10). Mitochondria-initiated calcium signaling plays 
an important role in setting up the cell death threshold impaired mitochondrial function [12] and 
slightly elevated cytoplasmic calcium (Fig. 2-11, Fluo-4 staining) were frequently found in 
gamitrinib-treated cells, even at non-toxic dose of the drug. Therefore, we hypothesized that 
calcium-mediated stress propagation can render cells sensitive to additional stresses, i.e. 
lowering the cell death threshold. A representative UPRER inducer, Thap, was combined with 
gamitrinib to test this hypothesis. Gamitrinib sensitized cancer cells to Thap treatment at various 
concentrations, while the nontargeted Hsp90 inhibitor 17AAG did not (Fig. 2-12A and C). 
Consistent with pharmacological data, TRAP1knockdown also sensitized cancer cells to Thap 
treatment (Fig. 2-12B and D). The combination drug treatment of gamitrinib and Thap elevate 
time dependent CHOP expression and the CHOP expression induced by combination treatment 
was faster and higher compared to single-agent treatment (Fig. 2-13A). A cell-based reporter 
assay also showed elevated CHOP transcription activity following combination treatment (Fig. 
2-13B). siRNA-mediated knockdown of either CHOP significantly suppressed this increased 
cytotoxic activity, but did not affect the toxicity seen with single agent treatment (Fig. 2-13C). 
The combination drug induced CHOP expression was a RyR-dependent manner and siRNA-
mediated knockdown of RyR significantly suppressed the CHOP expression and the cytotoxic 
activity (Fig. 2-14A and B). It suggests important roles of RyR and CHOP in the drug 
combination effect (Fig. 2-13C and 14A) and RyR opening is an essential upstream event in the 
stress response elevating CHOP expression. The combination of gamitrinib and Thap 
synergistically induced apoptotic cell death, causing a dramatic increase in caspase activity (Fig. 
2-15A). CHOP-dependent death receptor 5 (DR5) expression [46] has been reported before, but 
was not involved in the drug combination, considering marginal elevation of DR5 expression 
and no activation of caspase-8 (Fig. 2-15B and C) [47]. Collectively, our data argue that 
gamitrinib lowers the cellular threshold against ER stresses by increasing CHOP expression in 
an RyRdependent manner. 
 
Combined synergistic anticancer activities in vivo  
The mitochondrial Hsp90 pool is dramatically elevated in many cancer cells to cope with 
various stresses, but expression is very low or undetectable in most normal tissues except brain 
and testis [6, 7, 48-50]. To test whether mitochondrial Hsp90-regulated interorganelle calcium 
signaling is functional in normal cells, we examined primary astrocytes from mouse brain, 
where Hsp90 expression in mitochondria is higher than in other tissues [6]. Gamitrinib did not 
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affect CHOP induction and eIF2α phosphorylation (Figure 2-16A), whereas Thap increased 
CHOP expression in astrocytes (Fig. 2-16C). Gamitrinib treatment in combination with Thap 
did not sensitize astrocytes (Fig. 2-16B), possibly due to very low expression of both TRAP1 
and Cyp-D in astrocytes compared to cancer cells (Fig. 2-16D). Collectively, gamitrinib does 
not affect the cell death threshold in astrocytes, probably due to the limited contribution of the 
chaperones to PTP opening in normal cells; this is in stark contrast with data from cancer cells 
(Fig. 2-12A and C). Next, the gamitrinib and Thap combination was further examined using a 
xenograft of relapsed prostate cancer cells (22Rv1) [51], to test whether the cancer cell-specific 
lowering of the cell death threshold occurs in vivo. Because Thap has been reported to be highly 
toxic in vivo [52], we administered a very low dose of the drug. Suboptimal individual doses of 
Thap and gamitrinib did not result in significant inhibition of tumor growth, whereas combined 
treatment inhibited tumor growth (Fig. 2-17A) without remarkable histological abnormalities 
and body weight changes (Fig. 2-18A and B). Individual treatment with either gamitrinib or 
Thap slightly elevated CHOP expression, whereas combined treatment further elevated CHOP 
expression synergistically in cancer cells, but not in the brain or liver (Fig. 2-17B and 18C). 
Therefore, similar to the in vitro data, mitochondrial Hsp90 inhibition lowers the cell death 
threshold of cancer cells to Thap treatment in vivo (Fig. 2-19). 
 
 
 
2-4. Discussion 
 
Mitochondria are integrators of various cellular stress signals that eventually make life-or-
death decisions. We show here that mitochondria can also produce calcium mediated stress 
signals and propagate them to neighboring organelles. For calcium signaling, interplay between 
the permeability transition pore (PTP) in mitochondria and ryanodine receptor (RyR) in ER was 
essential, and the mitochondrial Hsp90 pool negatively modulates signal commencement in 
cancer cells to protect them from cellular stresses. TRAP1 knockdown by siRNA showed a 
similar phenotype to simultaneous inactivation of both Hsp90 and TRAP1 by gamitrinib. 
Considering functional overlap between Hsp90 and TRAP1 in the regulation of PTP in cancer 
cells [6, 53], the lack of functional compensation by the mitochondrial Hsp90 is quite 
unexpected, and may suggest different protein interaction networks between Hsp90 and TRAP1, 
or alternatively, that TRAP1 functionally dominates over Hsp90 in cancer mitochondria. There 
is growing consensus that mitochondrial Hsp90 and TRAP1 play important roles in neoplastic 
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progression by modulating a variety of mitochondrial pathways: metabolic reprogramming, 
mitochondrial dynamics, reactive oxygen species, autophagy, and cell death [53, 54]. Thus, to 
clearly address their roles in mitochondrial homeostasis and tumorigenesis, the relative 
contribution of the chaperones to the mitochondrial signal pathways and the functional 
relationship between them should first be discovered. 
Calcium, in such stress signaling, does not merely mediate mitochondria-ER communication, 
but is also critical for PTP and RyR calcium channel opening. Calcium released through one of 
the channels can trigger the opening of the other through calcium-induced calcium release 
(CICR) [15, 28], which can eventually amplify signals even with minute perturbation of 
mitochondrial chaperone functions. 
Interestingly, IP3Rs, major ER calcium channels allegedly requiring the ligand IP3 as well as 
calcium for CICR [42], are not involved in mitochondria-initiated calcium signaling, which 
further argues that the mitochondria-initiated pathway occurs through genuine CICR that is 
solely dependent on discharged calcium. Interplay and subsequent signal amplification between 
the calcium channels are crucial to signaling, as inhibition of either the PTP or RyR blocked 
calcium signaling. The unknown mechanism of CHOP induction after inactivation of 
mitochondrial Hsp90s in previous reports[4, 36-38] can be explained by this interplay. 
Furthermore, local calcium increases, seen as calcium hot-spots after low-dose gamitrinib 
treatment (Fluo-4 staining in Figure 2-5A), seem to be the consequence of the calcium channel 
interplay, which is sufficient to provoke global mitochondrial membrane potential reduction and 
UPR ER induction. Without a large increase in cytoplasmic calcium concentration, this is 
sufficient to propagate the stress response, probably due to the closely apposed architecture of 
the mitochondria and ER [23, 26, 27]. Thus, mitochondriainitiated calcium signaling might be 
further supported by the physical interconnection between mitochondria and the ER, which 
forms a specialized microdomain of transient calcium [24, 55] and can facilitate reciprocal PTP 
and RyR activation via CICR. Target-centered anticancer drugs often show limited efficacies, 
poor safety, and resistance profiles due to complicated signaling networks in many cancer cells 
[56, 57]. Multicomponent and system-oriented therapeutics development approaches could 
provide a solution [58, 59]. The target proteins of gamitrinib and Thap have fundamentally 
different functions in distinct organelles [6, 60, 61]. When combined, their anticancer activities 
were enhanced and non-toxic doses of the drugs were sufficient in vitro and in vivo to kill 
cancer, but not normal cells, through calcium-mediated coordination of compartmentalized 
signaling networks and synergistic elevation of CHOP expression. These pharmacological data 
further support the function of mitochondrial Hsp90s as important regulators of inter organelle 
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crosstalk, increasing the stress threshold, and identify these proteins as drug targets for the 
development of novel combination cancer therapy. Thus, we believe that mitochondrial Hsp90 
inhibitors require further system-oriented investigation to facilitate the development of an 
effective and better multi component anticancer regimen by combining antitumor drugs or even 
non-antitumor drugs capable of inducing organelle stress. 
In conclusion, Mitochondria-initiated and calcium-mediated propagation of the stress signal 
plays an important role in coordinating ER and mitochondrial stress responses, and is implicated 
in lowering the cell death threshold in cancer cells. Therefore, targeting the coordinated calcium 
stress signaling pathway often suppressed in cancer cells might be a feasible and effective 
strategy for the rational development of cancer therapeutics. 
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Figure 2-1. Mitochondrial Hsp90s modulate the mitochondrial calcium store  
(A) Time course of cytosolic calcium increase. The ratio of the emission fluorescence intensities 
at 340 and 380 nm excitation of Fura-2 labeled HeLa cell in calcium-free medium was 
measured after 30 μM gamitrinib treatment as described in Materials and Methods. (B) Increase 
of cytosolic calcium in 22Rv1 and MDA-MB-231 cells. Fura-2 fluorescence ratio after 30 μM 
gamitrinib (Gami) treatment for 1 hour was calculated. Data are the mean ± SEM of duplicated 
experiments and collected from 40 regions of interest (ROIs). (C) Cyclosporin A (CsA) blocks 
cytosolic calcium increase. Cytosolic calcium changes in Fura-2-labeled HeLa cells treated for 1 
hour with 5 μM CsA and/or 30 μM gamitrinib were analyzed. Bar, 50 μm. (D) No elevation of 
cytosolic calcium on 17AAG treatment. Fura-2 loaded HeLa cells were treated with a non-
targeted Hsp90 inhibitor, 17AAG, and analyzed using a fluorescence microscope.  
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Figure 2-2. Mitochondrial Hsp90s regulate PTP opening , caspase activation and cell death  
(A) Mitochondrial membrane permeabilization. TMRM-loaded HeLa cells were imaged to 
measure mitochondrial membrane potential depolarization (ΔΨm). *, p< 0.0001. (B) 
Cytochrome c redistribution was analyzed (right) at the indicated times after 30 μM gamitrinib 
treatment as previously described [62]. White bar, 20 μm. (C) Caspase activation and cell death 
induction. After 30 μM gamitrinib treatment, HeLa cells were labeled with FITC-DEVD-fmk 
(left, DEVDase activity) or propidium iodide (right, PI staining) and analyzed by flow 
cytometry at the selected time points. (D) Summary of sequential events following 
mitochondrial Hsp90 inhibition. PTP opening is directly linked with the loss of ΔΨm and 
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increase of cytosolic calcium. The calcium flux occurs prior to mitochondrial outer membrane 
permeabilization (MOMP) and cytochrome c release.  
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Figure 2-3. Inhibition of mitochondrial Hsp90s depletes stored calcium in both 
mitochondria and the ER  
(A) Mitochondrial calcium depletion. After 30 μM gamitrinib and 10 μM FCCP treatment, 
confocal FRET images of mtCameleon-expressing HeLa cells were reconstructed from their 
emission fluorescence ratios at 535/480 nm with excitation at 440 nm (left). FRET ratios at the 
indicated time intervals were averaged and plotted (right). (B) ER calcium depletion. FRET 
images of HeLa cells transiently expressing D1ER were acquired at the indicated time points 
after gamitrinib treatment (left) and analyzed to plot the FRET ratio (right). Selected ROIs are 
indicated as white circles. Bar, 10 μm. Data in (A) and (B) are mean ± SEM collected from 30 
ROIs. R.U., relative units. (C-D) Organelle specific effect of FCCP and Thap (C) TMRM loaded 
HeLa cells were treated with 10 μM FCCP or 10 μM Thap for 30 mins and analyzed by 
confocal microscope (left). Quantitation of the confocal microscope images (right). Data are 
mean ± SEM from 30 ROIs. #, not significant; *, p<0.0001. (D) HeLa cells were treated with 
the drugs for 2 hours and analyzed by western blotting (right).  
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Figure 2-4. Effect of 17AAG on the mitochondrial calcium store  
(A) mtCameleon was transiently expressed in HeLa cells. FRET images were acquired after 30 
μM 17AAG treatment at the indicated time intervals. (B) FRET ratio was calculated and plotted 
(right). Data are the mean ± SEM calculated from 30 cells in two independent experiments. Bar, 
10 μm. R.U., relative units.   
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Figure 2-5. Gamitrinib effect on normal cells 
(A) TMRM loaded MCF10A cells (breast normal cell line) were treated with 30 μM gamitrinib 
as indicated and analyzed by confocal microscope. (B) Quantitation of the images (right). Data 
are mean ± SEM from 40 ROIs. #, not significant; *, p<0.0001.  
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Figure 2-6. Inhibition of mitochondrial Hsp90s activates ER stress sensors  
(A) XBP1 splicing by silencing TRAP1. HeLa cells were treated with two different TRAP1 
siRNAs for 24 hours. mRNA expression levels of XBP1 splicing variants, TRAP1, and GAPDH 
were analyzed by RT-PCR. (B) eIF2α phosphorylation upon TRAP1 silencing. After treatment 
of HeLa cells with two different TRAP1 siRNAs, the expression levels of eIF2α, phospho-eIF2α 
(p-eIF2α), TRAP1, and β-actin were analyzed by western blotting. (C) XBP1 splicing upon 
mitochondrial Hsp90 inhibition. After treatment with 30 μM gamitrinib for 2 hours, mRNA 
expression levels of XBP1 splicing variants, TRAP1, and GAPDH mRNAs were analyzed by 
RT-PCR. (D) Analysis of CHOP mRNA. HeLa cells were treated with 30 μM gamitrinib or 
TRAP1 siRNAs as indicated. CHOP and GAPDH mRNAs were analyzed by RT-PCR. 
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Figure 2-7. Inhibition of mitochondrial Hsp90s induce ER stress depending on calcium  
CHOP induction and eIF2α phosphorylation. HeLa cells were treated with 30 μM gamitrinib, 5 
μM CsA, and 10 μM BAPTA as indicated and analyzed by western blotting.  
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Figure 2-8. Gamintrinib induced cytosolic calcium elevation is not involved in IP3 receptor  
(A) Silencing of IP3R isotypes. HeLa cells were treated with IP3R1-, IP3R2-, and IP3R3-
specific siRNAs, and analyzed by Western blotting. (B) IP3R silencing. After IP3R siRNA 
treatment, Fura-2 labeled HeLa cells were treated with 30 μM gamitrinib for 1 hour. The 
fluorescence ratio (340/380) was plotted. The data are mean ± SEM collected from 30 ROIs in 
two independent experiments. (C) IP3R knockdown effect on CHOP expression. Control or 
IP3R1 siRNA-transfected HeLa cells were incubated with or without 30 μM gamitrinib for 2 
hours. Cell extracts were analyzed by western blotting. (D) IP3R1 silencing blocked LPA-
induced calcium flux. HeLa cells were treated with IP3R1 siRNA and labeled with Fura-2. After 
LPA treatment, cytoplasmic calcium flux was monitored. Data are the mean ± SEM calculated 
from 20 ROIs in two independent experiments.  
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Figure 2-9. Ryanodine receptor (RyR)-mediated cytosolic calcium elevation  
(A) RyR inhibitors compromise cytosolic calcium increase. Fura-2 labeled HeLa cells were 
treated with 30 μM gamitrinib for an hour in the presence or absence of 300 μM tetracaine, 100 
μM ryanodine, and 5 μM CsA, and emission fluorescence intensity ratios (340/380 nm 
excitation) were measured. Data are mean ± SEM calculated from 40 ROIs in two independent 
experiments. (B) Fura-2 imaging and RyR2 silencing. Control or RyR2-#2 siRNA-treated HeLa 
cells were labeled with Fura-2 and imaged after 30 μM gamitrinib treatment for an hour (left). 
The fluorescence ratio (340/380) was plotted (middle). Knockdown efficiency of RyR2-#2 
siRNA by western blotting (right). The data are mean ± SEM collected from 30 ROIs in two 
independent experiments. Bar, 50 μm. (C) Inhibition of CHOP induction by RyR inactivation. 
HeLa cells were treated with 30 μM gamitrinib in the presence or absence of 100 μM ryanodine. 
Cell extracts were analyzed by western blotting. (D) RyR2 silencing and CHOP expression. 
HeLa cells were treated with two different RyR2 siRNAs, incubated with 30 μM gamitrinib, for 
2 hours and analyzed by western blotting.  
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Figure 2-10. Reactive oxygen species (ROS) does not affect gamitrinib-induced calcium 
release and CHOP induction 
(A) ROS do not affect gamitrinib-induced calcium release. Fura-2 loaded 22Rv1 cells were 
incubated with 30 mM N-acetylcysteine (NAC) or 30 μM MnTMPyP for 1 hour and then 
treated with 30 μM gamitrinib for 2 hours and analyzed by the fluorescence microscope. (B) A 
mitochondrial ROS scavenger effect on CHOP induction. 22Rv1 cells were treated with 20 μM 
gamitrinib in the presence or absence of 20 μM MnSOD for 4 and 8 hours and analyzed by 
western blotting. (C) A various ROS scavenger effect on CHOP induction. 22Rv1 cells were 
treated with 20 μM gamitrinib in the presence or absence of 0.5 mM ascorbic acid, 0.5 mM 
2,2,6,6 tetramethylpiperidine 1-oxyl (TEMPO), and 20 μM pyrollidine dithiocarbamate (PDTC) 
for 8 hours and analyzed by western blotting. 
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Figure 2-11. Cytoplasmic calcium and mitochondrial membrane potential by noncytotoxic 
dose of gamitrinib 
Calcium indicated Fluo-4 or TMRM/MitoTracker-labeled HeLa cells were incubated with 5 μM 
gamitrinib for 24 hours and analyzed by confocal microscope. Bar, 20 μm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
 
 
 
 
51 
 
Figure 2-12. Inhibition of mitochondrial Hsp90s sensitizes HeLa cells toward thapsigargin  
(A) Combination effect in HeLa. HeLa cells were treated with various concentrations of Thap in 
the presence of 5 μM of either 17AAG or gamitrinib, and analyzed by MTT assay (left). 
Alternatively, HeLa cells were treated with 5 μM gamitrinib and/or 0.06 μM Thap for 24 hours 
and analyzed by the MTT assay. ***, p < 0.0001. (B) Knockdown of TRAP1 by siRNA. After 
silencing of TRAP1 in HeLa with TRAP1-#1 siRNA, cells were treated with various 
concentrations of Thap for 24 hours and analyzed by the MTT assay.  Data are from three 
independent duplicate experiments; data are given in terms of mean ± SEM. (C) Combination 
effect in 22Rv1. 22Rv1 cells were treated with various concentrations of thapsigargin in the 
presence of 2.5 μM of either 17AAG or gamitrinib for 24 hours, and analyzed by the MTT assay 
(left). Alternatively, 22Rv1 cells were treated with 2.5 μM gamitrinib (Gami) and 0.06 μM Thap 
as indicated for 24 hours and analyzed by the MTT assay. **, p = 0.0006. (D) Knockdown of 
TRAP1 by siRNA. After silencing of TRAP1 in 22Rv1 cells with TRAP1-#1 siRNA, cells were 
treated with various concentrations of Thap for 24 hours and analyzed by the MTT assay.  Data 
are from three independent duplicate experiments; data are given in terms of mean ± SEM. 
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Figure 2-13. Gamitrinib and Thap combination treatment elevates CHOP expression  
(A) Synergistic increase in CHOP induction. 22Rv1 and H460 cells were treated with 5 μM 
gamitrinib and 0.06 μM Thap as indicated and analyzed by western blotting. (B) CHOP reporter 
assay. PC3 cells stably transfected with a CHOP::GFP reporter plasmid were incubated with 2.5 
μM gamitrinib and/or 0.02 μM Thap as indicated and analyzed as described in Materials and 
Methods (left). Cells with more than twice the background fluorescence intensity were 
considered as positive cells (right). Bar, 100 μm. Mean ± SEM. **, p = 0.0036. (C) Silencing 
CHOP expression. Control or CHOP siRNA-transfected HeLa cells were treated with 0.06 μM 
Thap and 5 μM gamitrinib for 24 hours, and analyzed by MTT assay. Knockdown efficiency 
analyzed by western blotting (bottom right). Mean ± SEM. *, p < 0.05.  
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Figure 2-14. Silencing RyR expression 
(A) Control or RyR siRNA-treated HeLa cells were incubated with 0.06 μM Thap and 5 μM 
gamitrinib for 24 hours, and analyzed by MTT assay. Knockdown efficiency analyzed by 
western blotting (bottom right). Mean ± SEM. *, p < 0.05. (B) Knockdown of RyR2 by siRNA. 
Control or RyR2 siRNA-transfected 22Rv1 cells were incubated with 2.5 μM gamitrinib and/or 
0.06 μM Thap as indicated and analyzed by western blotting.  
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Figure 2-15. Apoptosis induction on combination drug treated HeLa cells 
(A) Combination treatment induces apoptosis. HeLa cells were treated with 10 μM gamitrinib 
and 0.5 μM Thap as indicated, labeled with FITC-DEVD-fmk and propidium iodide, and 
analyzed by flow cytometry. (B) DR5 expression on combination drug treatment. 22Rv1 cells 
were treated with 2.5 μM gamitrinib and 0.06 μM Thap as indicated for 24 hours, then analyzed 
by reverse transcription (RT)-PCR. (C) caspase-8 activation on combination drug treatment. 
22Rv1 cells were treated with 2.5 μM gamitrinib and 0.06 μM Thap as indicated for 24 hours, 
then analyzed by western blotting. 
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Figure 2-16. CHOP induction and cytotoxicity in astrocytes  
(A) Astrocytes treated with 30 μM gamitrinib for 2 hours were analyzed by western blotting. 
(B) Thap in combination with gamitrinib. Astrocytes were treated with various concentrations of 
Thap in the presence of 0, 2.5, 5, or 10 μM gamitrinib and the cell viability was analyzed by 
MTT assay. Data are from three independent experiments. (C) Gamitrinib and Thap treatment in 
astrocytes. Astrocytes were treated with 10 μM Thap or 30 μM gamitrinib for 4 hours and 1 μM 
Thap or 2.5 μM gamitrinib for 24 hours, and analyzed by western blotting. (D) TRAP1 
expression in astrocytes. TRAP1 and cyclophilin D (Cyp-D) expression in astrocytes isolated 
from mouse brain was compared with cancer cell lines by western blotting.  
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Figure 2-17. Synergistic cancer-specific cytotoxicity in vivo  
(A) Tumor xenograft experiment. Subcutaneous 22Rv1 xenografts were established as described 
in Materials and Methods. At the end of the experiment, final tumor volumes were plotted 
(right). We used five mice per group and two tumors per animal. (B) Analysis of CHOP 
expression in liver and tumor. Liver and tumor samples from three randomly selected mice for 
each treatment (total 12 mice) were analyzed by western blotting (left). After normalization of 
CHOP band intensities with β-actin, relative CHOP intensities were calculated (right). ***, p= 
0.0003; *, p = 0.039; #, p> 0.1. 
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Figure 2-18. Side effect on combination drug administration in vivo  
(A) Mouse body weight change. Prior to sacrificing the animals in the xenograft experiment, 
their body weights were measured. Data are mean ± SEM. (B) Hematoxylin and eosin staining. 
The animals were sacrificed at the end of the experiment, and organs were collected, fixed, 
stained, and analyzed under a light microscope. (C) Analysis of CHOP expression in mouse 
brain. Brain samples from sacrificed mice (total 8 mice) were analyzed by western blotting. 
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Figure 2-19. Schematic diagram of the mitochondria-initiated stress signal 
Chemical inhibitors are indicated in red. 
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Chapter 3. Combination treatment with doxorubicin and 
gamitrinib synergistically augments anticancer activity 
through enhanced activation of Bim. 
 
3-1. Introduction 
Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that controls folding 
of a wide range of protein substrates, or clients, many of which are involved in signal pathways 
crucial for tumorigenesis [1, 2]. The primary cellular location of Hsp90 is the cytoplasm, but a 
pool of Hsp90 and its isoform, tumor necrosis factor receptor-associated protein 1 (TRAP1), has 
been reported in mitochondria [3, 4]. The mitochondrial expression of Hsp90 and TRAP1 is 
often elevated in many cultured cancer cells and human cancer patients tumorigenic processes 
including the neoplastic metabolic shift to aerobic glycolysis [5-7] and inhibition of cell death 
[3]. A class of mitochondriotropic Hsp90 inhibitors, named gamitrinibs (GA mitochondrial 
matrix inhibitors), has been developed through combinatorial chemistry [8]. Gamitrinibs consist 
of geldanamycin, a competitive inhibitor of the ATPase pocket of Hsp90 and TRAP1, 
conjugated with tandem repeats of tetracyclic guanidinium tumor triphenylphosphonium for 
mitochondrial targeting [8, 9]. Gamitrinibs not only trigger massive cell death in cultured cancer 
cells in vitro but also strongly suppress tumor growth in various xenograft and genetic mouse 
cancer models in vivo [8, 10, 11]. The gamitrinib-induced cytotoxicity is attributed to the 
reactivation of cyclophilin D (Cyp-D), an opener of the permeability transition pore (PTP) 
located in the mitochondrial inner membrane [3, 12]. Because such opening of the PTP can be 
lethal, Cyp-D activation is often suppressed in cancer cells by interaction with mitochondrial 
Hsp90s, which increase resistance to various cellular stresses [3]. In addition, gamitrinibs have 
been shown to induce organelle-specific stress responses and dysregulation of bioenergetics in 
mitochondria of cancer cells, concomitantly compromising neoplastic growth [7, 13-15]. 
Doxorubicin (DOX), an anthracycline antibiotic with the trade name Adriamycin, is one of the 
most effective anticancer drugs and has been widely used in various chemotherapeutic regimens 
to treat patients with cancer [16]. The antitumor activities of DOX are primarily attributed to 
DNA damage resulting from the inhibition of DNA topoisomerase II [16, 17]. The clinical use 
of DOX, however, has been limited by the risk of cardiotoxicity, which is dependent on the 
cumulative dose/treatment schedule, typically refractory to common medications, and can be 
fatal [17-19]. Here, we examined whether a combination of two cytotoxic drugs with unrelated 
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action mechanisms, DOX (genotoxic) and gamitrinib (mitochondriotoxic), would exhibit 
enhanced anticancer activity without aggravating unwanted side effects. This drug combination 
showed synergistically increased anticancer activities in vitro and in vivo, without augmenting 
cardiomyocyte toxicity. The underlying mechanism of action involved the activation of a 
proapoptotic Bcl-2 protein following the stimulation of CHOP and JNK pathways in cancer 
cells. 
 
 
 
3-2. Materials and methods 
 
Chemicals and antibodies 
Gamitrinib conjugated with triphenylphosphonium was prepared as described previously [10]. 
MitoTracker, JC- 1, and tetramethylrhodamine methyl ester (TMRM) were purchased from 
Molecular Probes. All other chemicals were purchased from Sigma. The following antibodies 
were used in this study: anti- JNK, anti-phospho-JNK (Thr183/Tyr185), anti-COX-IV, and anti-
CHOP from Cell Signaling Technology; anticytochrome c, anti-Bim, and anti-PARP from Santa 
Cruz Biotechnology; anti-β-actin from MP Biomedicals; and anti-TRAP1, anti-Bax, anti-
caspase-8, and anti-caspase-3 from BD Biosciences. 
 
Cells and cell culture 
Human cancer cell types that originated from ovary (SKOV3), prostate (22Rv1 and PC3), 
cervix (HeLa), breast (MDA-MB-231), liver (SK-HEP-1), brain (A172), kidney (ACHN), and 
lung (NCI-H460) were purchased from the Korean Cell Line Bank. Cells were cultured in 
DMEM or RPMI (GIBCO) medium containing 10% FBS (GIBCO) and 1% 
penicillin/streptomycin (GIBCO) at 37°C in a 10% CO2 humidified atmosphere. 
 
siRNA treatment 
Small interfering RNAs (siRNAs) against JNK and CHOP were synthesized by Genolution Inc 
(Korea). siRNA sequences used in this study were as follows: 
JNK1-#1, 5′-AAAGAATGTCCTACCTTCTCT-3′; JNK1-#2, 5′-AAGCCCAGTAATATAGTA 
GTA-3′; CHOP-#1, 5′-AGAACCAGCAGAGGTCACAA-3′; CHOP-#2, 5′-AAGAGAATGA 
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ACGGCTCAAGC-3′; Bim-#1, 5′-GCAACCTTCTGATGTAAGT-3′; Bim-#2, 5′-GACCG 
AGAAGGTAGACAATT-3′ and control, 5′-ACUCUAUCUGCACGCUGAC-3′. 
 
Cells were cultured on 6-well plates to 50–75% confluence, transfected with 40 nM siRNA 
mixed with G-Fectin (Genolution) for 48 hours, and then analyzed or treated with drugs. 
 
Analysis of cell viability and apoptosis induction 
Cell viability was determined using 3(4,5-dimethyl-thyzoyl-2-yl)2,5 diphenyltetrazolium 
bromide (MTT) and quantified by absorbance at 595 nm. Percent viability was determined by 
comparison with vehicle-treated control samples. To measure apoptosis, DNA content 
(propidium iodide or sytox staining), externalized phosphatidylserine (Annexin V) and caspase 
activation (DEVDase activity) of the cells were determined using the CaspaTag in situ apoptosis 
detection kit (Millipore) and Dead Cell Apoptosis Kit with Annexin V APC and SYTOX®  
Green (Molecular probes). Labeled cells were analyzed using a FACS Calibur™ flow cytometer 
(BD Biosciences). Data were processed using FlowJo software (TreeStar).  
 
Western blot analysis and mitochondrial fractionation 
Mitochondrial fractionation from cultured cells was performed with a Mitochondrial Isolation 
kit (Thermo Scientific) as described in the manufacturer’s instructions. For western blot analysis, 
proteins were separated on 8-12% SDS-polyacrylamide gels and transferred to polyvinyl 
difluoride membranes (Millipore). Primary antibodies were diluted 100–5,000-fold, and 
horseradish peroxidase-conjugated mouse or rabbit secondary antibodies (KLP Inc.) were 
diluted 5,000-fold. The ECL reagent (GE Healthcare) was used for chemiluminescence 
detection with a LAS 4000 imager (GE Healthcare). Tumor xenograft experiment All 
experiments involving animals were approved by the Ulsan National Institute of Science and 
Technology Animal Care and Use Committee (approval number:UNISTIACUC-12-003-A). 
Cancer cells (7 × 10
6
 22Rv1 or 1 × 10
7
 MDA-MB-231) were suspended in sterile 200 μl PBS. 
22Rv1 cells were injected subcutaneously into both flanks of 8-week-old BALB/c nu/nu male 
mice (Japan SLC Inc.). MDA-MB-231 cells were orthotopically injected into the mammary fat 
pad of 8-week-old BALB/c nu/nu female mice. Gamitrinib or vehicle (DMSO) dissolved in 
20% Cremophor EL (Sigma) in PBS was injected intraperitoneally (i.p.), and DOX diluted in 
PBS was injected intravenously (i.v.). The mice were treated with 10 mg/kg gamitrinib and/or 3 
mg/kg DOX twice a week according to the group. Tumors were measured daily with a calliper 
and tumor volume was calculated using the formula V =1/2 × (width)
2
 × length. At the end of 
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the experiment the animals were euthanized, and organs including brain, heart, kidney, liver, 
lung, spleen, stomach, intestine, and testis, and tumors were collected for histologic or western 
blot analyses. Blood was also collected for measurement of serum creatine phosphokinase 
activity using the Indiko and Konelab System CK (Thermo Scientific) according to the 
manufacturer’s instructions. 
 
RNA extraction and reverse transcript-PCR  
Total RNA was prepared from cells suspended in cold PBS using the RNeasy mini kit 
(QIAGEN), and cDNA was synthesized using the ProtoScript®  First Strand cDNA Synthesis 
Kit (New England Biolabs) using an oligo(dT) primer. The PCR reaction was performed in a 
Mastercycler PCR machine (Eppendorf) with the following sets of oligonucleotide primers: 
 NOXA, 5′-GTGCCCTTGGAAACGGAAGA-3′ and 5′-CCAGCCGCCCAGTCTAATCA-3′; 
PUMA, 5′-CAGACTGTGAATCCTGTGCT-3′ and 5′-ACAGTATCTTACAGGCTGGG-3′; 
DR5,5′-TGCAGCCGTAGTCTTGATTG-3′ and 5′-GAGTCAAAGGGCACCAAGTC-3′; Bcl-2, 
5′-TTTTAGGAGACCGAAGTCCG-3′ and 5′-AGCCAACGTGCCATGTGCTA-3′;Bim, 5′- 
ATGGCAAAGCAACCTTCTGA-3′ and 5′-GGAAGCCATTGCACTGAGA-3′; CHOP, 5′-
CTTTCTCCTTCGGGACACTG-3′ and 5′-AGCCGTTCATTCTCTTCAGC-3′ GAPDH, 5′-
GGGAAGCTTGTCATCAATG-3′and 5′-GCAGTGATGGCATGGACT-3′. 
 
Statistical analyses 
Data from MTT assay (triplicate experiments independently repeated at least two times) were 
averaged and statistically analyzed by unpaired t-test using Prism 5.0 (GraphPad). A p-value 
less than 0.05 was considered significant. To investigate the synergistic efficacy of the drug 
combination, the combination index (CI) was determined according to the Chou-Talalay method 
using CalcuSyn software version 2.1 (Biosoft)[20]. 
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3-3. Results 
 
Gamitrinib-doxorubicin combination treatment showed synergistic enhancement of 
cytotoxicity in various cancer cell lines 
To investigate the effect of combination treatment with DOX and gamitrinib, cancer cell lines 
originating from cervix (HeLa), ovary (SK-OV3), and prostate (22Rv1) were treated with the 
drugs as single agents or in combination. Gamitrinib sensitized HeLa, SK-OV3, and 22Rv1 
cells to a wide range of DOX concentrations (Fig. 3-1A). Consistently, the drug combination 
enhanced cytotoxic effects compared with single agent treatment and resulted in cancer cell 
death at suboptimal concentrations (Fig. 3-1B). In contrast to the effect on cancer cells, 
gamitrinib did not sensitize cardiomyocytes to DOX treatment (Fig. 3-1C), suggesting no 
enhancement of cytotoxicity to normal cells with the drug combination. To further examine the 
combination effect, we calculated the combination index (CI) in various cancer cells using the 
Chou-Talalay method [21, 22]. The DOX and gamitrinib combination showed synergistic 
anticancer activity (CI<0.9) in all cancer cell types tested at a 50% effective dose: high 
synergism (CI<0.7) for HeLa (Fig. 3-1D), A172 (glioblastoma), ACHN (renal cell carcinoma), 
SK-HEP-1 (hepatocellular carcinoma), NCI-H460 (lung carcinoma), and SK-OV-3; and 
moderate synergism (0.7<CI<0.9) for 22Rv1 and MDA-MB-231 cells (Table 1). 
 
Combination of DOX and gamitrinib augments apoptotic cell death 
To address the cell death mechanism of the drug combination, propidium iodide uptake and 
caspase activation were analyzed by flow cytometry. Single drug treatment at a suboptimal 
concentration did not increase caspase activity significantly compared with the DMSO-treated 
control, whereas the drug combination dramatically increased caspase activity and concomitant 
cell death (Fig. 3-2A). Cell extracts from SK-OV3 and 22Rv1 consistently showed caspase 
activation, i.e., decreased amount of pro-form and an increase in the mature form of caspase-3 
and cleavage of the caspase substrate protein, poly (ADP-ribose) polymerase (PARP), for the 
combined drug treatment but not for single agent treatment (Fig. 3-2B). These data suggest that 
the drug combination synergistically augments apoptotic cell death by mediating caspase 
activation. Activation of caspase by the drug combination was completely inhibited by the pan-
caspase inhibitor zVAD-fmk (Fig.3- 2B). In addition, the enhanced cytotoxic activity of the drug 
combination was almost completely abrogated by zVAD-fmk (Fig. 3-2C), providing further 
evidence that the drug combination activates caspases and triggers the apoptotic cell death 
program. DOX does not act directly on cancer cell mitochondria Gamitrinib is designed to 
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accumulate in mitochondria and open the PTP, resulting in the induction of sudden cell death in 
various cancer cell types[10]. Some reports have suggested that the cytotoxicity of DOX is 
similarly attributed to direct opening of the PTP in mitochondria [17]. Therefore, we asked 
whether the observed drug synergism is associated with the direct effect of DOX on 
mitochondria. Treatment of cultured 22Rv1 cells with 5uM gamitrinib and 0.5uM DOX had 
only a marginal effect on mitochondrial outer (Fig. 3-3A) and inner membrane permeabilization 
(Fig.3-3B), whereas combined treatment with the two drugs dramatically increased the 
permeability of mitochondrial membranes based on discharge of cytochrome c into the 
cytoplasm (Fig. 3-3A) and loss of mitochondrial membrane potential (Fig. 3-3B). However, 
with isolated mitochondria, DOX alone had no effect on the membrane, whereas gamitrinib had 
a direct permeabilizing effect on mitochondrial membranes (Fig. 3-3C and 3D) as previously 
described [10] and the drug combination did not further increase membrane permeability (Fig. 
3-3C and 3D). These data suggest that DOX does not affect mitochondria directly, but instead 
affects signaling pathways outside the mitochondria that enhance mitochondrial membrane 
permeabilization and lead to mitochondrial apoptotic cell death. Confocal microscopic analysis 
showed that DOX was primarily accumulated in the extramitochondrial space (Fig.3-3E), 
further supporting indirect effects of DOX on mitochondria.  
 
Reactive oxygen species are not involved in the cytotoxic effect of combination treatment  
DOX has been reported to trigger production of reactive oxygen species (ROS), although the 
role of ROS in the induction of cancer cell death is controversial [17]. To examine the 
contribution of ROS to the cytotoxic effects of the drug combination, we examined the effect of 
a ROS scavenger on cytotoxic activity in HeLa cells after treatment with gamitrinib and DOX, 
alone or in combination. DOX alone increased the production of ROS (Fig. 3-4A, left panels), 
and the cytotoxic activity of DOX was not affected by co-treatment with the ROS scavenger N-
acetylcysteine (NAC) (Fig. 3-4B). Gamitrinib treatment increased the production of ROS in a 
dose-dependent manner (Fig 3-4A, middle panels), but NAC did not inhibit the cytotoxic 
activities of gamitrinib (Fig 3-4C). There was no additional increase in ROS production with the 
drug combination compared with single agent treatment (Fig. 3-4A, right panels), and NAC did 
not affect the cytotoxicity of the drug combination (Fig. 3-4D). These results indicate that ROS 
production is not involved in the enhanced cytotoxic activities of the drug combination.  
 
Gamitrinib and DOX combination treatment activates expression of CHOP and Bim  
DOX has been reported to modulate stress signal pathways such as the c-Jun Nterminal kinase 
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(JNK) and ER-stress induced C/EBP homologous protein (CHOP) pathways [23-25]. 
Gamitrinib can also activate JNK and induce CHOP by triggering an organelle-specific stress 
response, the mitochondrial unfolded protein response (UPR) [16, 26]. Therefore, we 
investigated the effect of combined DOX and gamitrinib on stress signaling and found that JNK 
activation (phosphorylation) and CHOP induction were increased more by the drug combination 
than by single agent treatment in 22Rv1 cells (Fig. 3-5A). Treatment with CHOP-specific 
siRNA reduced the enhanced cytotoxicity after combined drug treatment but did not affect 
cytotoxicity of single agent treatment (Fig. 3-5C), whereas JNK-specific siRNA did not affect 
the cytotoxic activity of the drugs singly or in combination. These data suggest that induction of 
CHOP is required for the combination effect of the drugs in 22Rv1 cells. As a downstream 
effector, the proapoptotic BH3-only Bcl-2 protein, Bim, is regulated by CHOP [27]. The 
expression of Bim was enhanced by the drug combination in 22Rv1 cells and knockdown of 
CHOP compromised the up-regulation of Bim (Fig. 3-5D). Consistent with these findings, 
inactivation of Bim by siRNA treatment compromised the enhanced cytotoxicity of the drug 
combination (Fig. 3-5B). Collectively, our data indicate that simultaneous genotoxic and 
mitochondrial proteotoxic stresses triggered by the DOX-gamitrinib combination can 
synergistically induce the transcription factor CHOP, which in turn increases Bim expression 
leading to the induction of cell death. Bim transcription was elevated, but expression of other 
Bcl-2 family proteins, such as Bcl-2, Puma, and Noxa, was not affected by the drug 
combination (Figure 3-6). Expression of death receptor 5 (DR5) was elevated by the drug 
combination in a CHOP-dependent manner (Figure 3-6) as described previously [28], while 
procaspase-8, recruited to the death inducing signaling complex (DISC) after DR5 activation 
[21], was not cleaved at all (Figure 3-6). These data suggest the crucial role of Bim expression 
in the drug combination. 
 
Gamitrinib and DOX combination treatment enhances mitochondrial localization of Bim 
and Bax.  
In contrast to 22Rv1 cells, the drug combination did not induce CHOP expression in HeLa and 
MDA-MB-231 cells (Fig. 3-7A). In HeLa cells, knockdown of JNK compromised the enhanced 
cytotoxicity of the drug combination (Fig. 3-7B) whereas knockdown of CHOP did not affect 
the drug synergism. To confirm proteosome degradation of CHOP or Bim, we checked the 
expression in presence or absence of MG132, proteosome inhibitor, and observed that CHOP 
and Bim protein were degraded on combination drug treatment (Fig. 3-8A). These data suggest 
that there are context-dependent disparate stress responses to the drug combination, and the 
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JNK pathway, but not CHOP, can be critically involved in the synergistic combination effect in 
certain cancer cell types. Previous studies have shown that JNK can activate Bim through 
phosphorylation to trigger Bax-dependent mitochondrial apoptosis [29-32]. Phosphorylated Bim 
was detectable in HeLa and MDA-MB-231 cells, but not in 22Rv1 (Fig. 3-5A and 7A). 
Treatment with the drug combination caused increased accumulation of Bim and Bax in the 
mitochondria, which was significantly reduced by the JNK inhibitor SP600125 (Fig. 3-8C, left). 
Bim that accumulated in mitochondria was a slow-migrating phospho-form of the protein 
(Fig.3-8C, right panel). The combination effect was compromised by treatment with Bim siRNA 
(Fig. 3-7C), further supporting the important role of the proapoptotic Bcl-2 protein in the drug-
induced stress response [33]. Collectively, these data indicate that the DOX-gamitrinib 
combination enhances JNK-mediated Bim phosphorylation, which triggers translocation of Bax 
to the mitochondria and augments mitochondrial apoptosis. 
 
Drug combination treatment effectively inhibited tumor growth in vivo 
We further investigated the efficacy of the drug combination in vivo using two xenograft 
models for prostate and breast cancer. Firstly, gamitrinib has shown anticancer activity as a 
single agent against prostate cancers in vivo[11, 13, 14, 34], therefore we examined the 
anticancer activity of gamitrinib in the presence of DOX using a prostate cancer xenograft 
model with the hormone-independent relapsed human prostate cancer cell line 22Rv1[35, 36]. 
Single treatment with gamitrinib or DOX resulted in a slight reduction in tumor volume, 
whereas combination treatment dramatically suppressed tumor growth (Fig. 3-9A). Secondly, 
DOX is frequently used to treat early and metastatic breast cancers in the clinic [37, 38]; 
therefore we tested the effect of the drug combination on an orthotopic xenograft model with the 
triple negative (ER-negative, PR-negative, and no HER2 overexpression) metastatic breast 
cancer cell line MDA-MB-231 [39]. The tumor growth was strongly inhibited by the drug 
combination but not by single agent treatment (Fig. 3-9B). Histologic analysis of organs did not 
show any prominent differences among the groups except for the heart (Fig. 3-10A and 11), and 
there was a marginal reduction in mouse weight with the combination treatment (2.5% loss of 
body weight at the end of the experiment compared with the start). 
 
In vivo cardiotoxic side effects and mode of action of the drug combination. 
 A close examination of heart tissues from the treated mice showed a cardiotoxic phenotype of 
cytoplasmic vacuolization with similar severity for DOX alone and in combination treatment 
(Fig. 3-10A). The serum creatine phosphokinase (CPK) level was measured as an index of 
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cardiotoxicity [40, 41] at the end of the experiment (Fig. 3-10B). DOX treatment alone 
increased the level of CPK; this increase was reduced with the combination treatment, but the 
difference between single and combination treatment was not significant (Fig. 3-10B). These 
data suggest that the DOX-induced cardiotoxicity is not aggravated by the drug combination. 
Next, we analyzed the mechanism underlying the activity of the drug combination in vivo. 
Consistent with the in vitro data, the drug combination synergistically increased the 
phosphorylation of JNK in whole tumor tissue extracts (Fig. 3-9C) and the accumulation of Bim 
and Bax in mitochondrial fractions (Fig. 3-9D). 
 
 
 
3-4. Discussion 
 
In this study, DOX, one of the most widely used anticancer drugs, was combined with the 
mitochondria-stress inducer, gamitrinib, to exploit disparate stress pathways in cancer therapy. 
Combination of these agents synergistically increased cancer-specific cytotoxic activity through 
stimulation of JNK and CHOP stress signalling pathways and activation of the proapoptotic 
protein Bim. Importantly, the drug combination did not aggravate the well-known cardiotoxic 
side effects of DOX in vitro or in vivo. Both gamitrinib[13, 14] and DOX [33, 35] have 
previously been shown to activate JNK and CHOP signalling pathways. Turning on these stress 
pathways activates the proapoptotic Bcl-2 family protein Bim through elevated gene expression 
and/or phosphorylation, leading to mitochondrial cell death [37, 42]. As a result of simultaneous 
stimulatory effects on the stress pathways by DOX and gamitrinib, the drug combination is able 
to further increase the amount of Bim protein (through CHOP elevation) and/or mitochondrial 
accumulation of Bim (through JNK activation), leading to enhanced mitochondrial 
accumulation of Bax and synergistic induction of apoptotic cell death. Combining cancer drugs 
with disparate mechanisms of action is a feasible strategy to increase therapeutic efficacy while 
avoiding unacceptable side effects of the drugs [38]. In this regard, combined treatment of DOX 
with other cancer drugs has been examined before and some of these combinations, for example 
with taxane or trastuzumab, have shown much more severe cardiotoxic side effects even at 
lower cumulative doses [16]. The combination of DOX and gamitrinib, however, did not 
aggravate cytotoxicity to cardiomyocytes in vitro or in vivo. We presume that cardiomyocytes 
are relatively resistant to gamitrinib because they are less dependent on mitochondrial 
chaperone functions to maintain protein homeostasis and cope with stresses under normal 
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physiologic conditions. In conclusion, combined treatment of DOX and gamitrinib showed 
synergistically enhanced cancer-specific toxicity without aggravating cardiotoxic side effects. 
The drug combination can realize the full potential of the anticancer activity of the individual 
drugs and broaden the application of the drugs to various cancer types. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
 
 
Table 3-1. Combination Index (CI) values at ED50 and ED75 in various cancer  
cell lines 
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Figure 3-1. Combination treatment with DOX and gamitrinib  
(A) Gamitrinib sensitizes cancer cells to DOX treatment. HeLa, SK-OV3, and 22Rv1 cells were 
treated with various on centrations of DOX in the absence (open circles) or presence of 5 μM, 
10 μM, and 2.5 μM gamitrinib (closed circles), respectively, for 24 hours. Cell viability was 
analyzed by MTT assay. Percent viability was expressed as a percentage relative to 0 μM DOX-
treatment. (B) DOX and gamitrinib were added as a single agent or in combination to the 
following cancer cells: SKOV3 (10uM/10uM gamitrinib), 22Rv1 (0.25uM DOX/2.5uM 
gamitrinib), and HeLa (2uM DOX/5uM gamitrinib). Cells were treated with the drugs for 
24hours and analyzed by MTT assay. The cell viability compared with that of DMSO treated 
control was plotted as a percentage. Data are the mean±SEM of two independent experiments 
performed in triplicate. (C) Effect of combination treatment on cardiomyocytes. Mouse primary 
cardiomyocytes were treated in the absence (open circles) or presence (closed circles) of 5 μM 
gamitrinib for 24 hours and analyzed by MTT assay. (D) Graphical representation of 
combination index (CI) for HeLa cells. The MTT data were analyzed using CalcuSyn software 
to generate CI values. The 95% confidence interval of CI (mean ± 1.96 × standard deviation) is 
depicted as dotted lines. 
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Figure 3-2. Induction of apoptosis by combination treatment  
(A) Cell death analysis. 22Rv1 and MDA-MB-231 cells were treated with 0.25 μM DOX/2.5 
μM gamitrinib and 10 μM DOX/5 μM gamitrinib, respectively, as single agents or combination 
treatment for 24 hours, and analyzed for propidium iodide, Sytox, Annexin V staining, and 
DEVDase activity by flow cytometry. The percentage of cells in each quadrant is indicated. (B) 
Caspase activation by the drug combination. 22Rv1 cells were treated with 0.25 μM DOX and 
2.5 μM gamitrinib, and analyzed by western blotting. The pan-caspase inhibitor zVAD-fmk was 
used at a concentration of 10 μM. (C) Effect of caspase inhibitor on the drug combination 
treatment. 22Rv1 cells were treated with 0.25 μM DOX, 2.5 μM gamitrinib, and 10 μM zVAD-
fmk as indicated and analyzed by MTT assay. Percent viability compared with DMSO-treated 
control is shown. Data are the mean ± SEM of duplicated three independent experiments  
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Figure 3-3. Effect of DOX on cancer cell mitochondria 
(A) Discharged cytochrome c in cytoplasm. HeLa cells were treated with 5uM gamitrinib and 
0.5uM DOX alone or in combination for 24 hours and cytosolic fractions were analyzed by 
western blotting. (B) JC-1 staining of HeLa cells. Cells were treated as in (A) labelled by JC-1 
staining[43], and analyzed by flow cytometry. The percentage of lost membrane potential is 
indicated (C) Cytochrome c release from isolated mitochondria. HeLa mitochondria were 
treated with 10uM gamitrinib and 1uM DOX alone or in combination. After centrifugation, the 
mitochondrial pellet (P) and supernatant (S) were analyzed by western blotting. (D) Membrane 
potential of isolated mitochondria. Mitochondria isolated from HeLa cells were treated with the 
drugs at the same concentration as in (C), stained with TMRM and analyzed by flow cytometry. 
(E) Confocal imaging of DOX localization. HeLa cells with stable overexpression of Bcl-2 were 
labelled with Mitotracker (green), treated with 10uM DOX (red) for 24hours and analyzed by 
confocal microscopy. Fluorescence intensity of the cytoplasm was further analyzed as a 
histogram (upper panel). White bar, 10um 
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Figure 3-4. Effect of reactive oxygen species on the drug combination effect 
(A) ROS production in HeLa cells. CM-H2DCFDA-labeled cells were treated with DOX and 
gamitrinib as indicated for 24 hours and anlayzed by flow cytometry. (B) Effect of ROS 
scavenger on DOX cytotoxicity. HeLa cells were treated with 5uM DOX in the presence or 
absence of 20mM N-acetylcysteine(NAC) for 24 hours. (C) Effect of ROS scavenger on 
gamitrinib cytotoxicity. HeLa cells were incubated with 2uM gamitrinib in the absence or 
presence of 20mM NAC for 24 hours. (D) Effect of ROS-scavenger on drug combination 
cytotoxicity. HeLa cells were co-treated with 5uM DOX and 2uM gamitrinib for 24 hours. In 
(A)-(D), cells stained with CM-H2DCFDA and propidium iodide were analyzed by flow 
cytometry. 
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Figure 3-5. Effect of drug combination on the expression of CHOP and Bim 
(A) CHOP induction and JNK phosphorylation. 22Rv1 cells were treated with DOX and 
gamitrinib alone or in combination as indicated and the whole cell lysate was analyzed by 
western blotting. (B) CHOP knockdown and Bim expression. After treatment with control or 
CHOP-#1 siRNAs, 22Rv1 cells were incubated with DOX and gamitrinib alone or in 
combination for 24 hours as indicated and cell extracts were analyzed by western blotting. (C) 
CHOP knockdown. 22Rv1 cells were treated with control or CHOP siRNAs for 24 hours and 
then with 0.25 μM DOX and 2.5 μM gamitrinib for 24 hours as indicated. The cell viability was 
analyzed by MTT assay. Data are mean ± SEM of two independent experiments performed in 
triplicate.*, p < 0.05; **, p < 0.004. (D) Effect of combination drug treatment after Bim 
silencing. After treatment with Bim siRNA, 22Rv1 cells were incubated with 0.25 μM DOX and 
2.5 μM gamitrinib for 24 hours as indicated and cell viability was analyzed by MTT assay. Data 
are mean ± SEM of two independent experiments performed in triplicate. *, p < 0.05.  
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Figure 3-6. Expression of Bcl-2 family proteins and DR5 
22Rv1 cells were treated with 0.25 μM DOX and 2.5 μM gamitrinib for 24 hours as indicated. 
After extraction and reverse transcription of RNA, the cDNA of interest was amplified by PCR. 
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Figure 3-7. Enhancement of JNK-mediated Bim phosphorylation by drug combination 
treatment  
(A) Phosphorylation of JNK and Bim. HeLa and MDA-MB-231 cells were treated with DOX 
and gamitrinib alone or in combination for 24 hours as indicated and analyzed by western 
blotting. (B) JNK silencing compromises the synergistic effect of combination treatment. HeLa 
cells were treated with JNK siRNA prior to treatment with 2 μM DOX and 5 μM gamitrinib as 
indicated for 24 hours. Cell viability was analyzed by MTT assay. Data are mean ± SEM of two 
independent experiments performed in triplicate. *, p < 0.02; **, p = 0.0004. (C) Effect of Bim 
silencing. After treatment with control or Bim-specific siRNAs, HeLa cells were incubated with 
2 μM DOX and 5 μM gamitrinib for 24 hours as indicated and analyzed by MTT assay. Data 
show mean ± SEM of two independent experiments performed in triplicate. ***, p < 0.0001. 
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Figure 3-8. Effect of MG132 and SP600125 
(A) MG132 effect on Bim and CHOP expression. HeLa cells were treated with 5 μM gamitrinib, 
2 μM DOX, and 30 μM MG132 as indicated, and analyzed by western blotting. (B) Inhibition of 
JNK activity by SP600125. HeLa cells were treated with 5 μM gamitrinib, 2 μM DOX, or 10 
μM SP600125 as indicated and analyzed by western blotting. The inhibition of JNK activity 
reduces phosphor-form (auto-phosphorylation) of the protein. (C) Mitochondrial accumulation 
of Bim and Bax. After treatment of HeLa cells with 5 μM gamitrinib, 2 μM DOX, or 10 μM 
SP600125 as indicated, mitochondria were fractionated and analyzed by western blotting (left).  
Bim phosphorylation in the whole cell extract and the mitochondrial fraction (right). 
 
 
 
 
91 
 
 
 
92 
 
Figure 3-9. Drug combination effect in vivo 
(A) Prostate cancer xenograft. 22Rv1 cells (7 × 10
6
 cells) were injected subcutaneously into 
both flanks of nude mouse (5 mice/group). After tumors were established, mice were treated 
twice a week with 3 mg/kg DOX i.v. and 10 mg/kg gamitrinib i.p. as single agents or in 
combination. (B) Orthotopic xenograft of breast cancer cells. MDA-MB-231 cells (1 × 10
7
 
cells) were grown in mammary fat pads of nude mouse (3 mice/group). Mice were treated twice 
a week with 3 mg/kg DOX i.v. and 10 mg/Kg gamitrinib i.p. as single agents or in combination. 
(C) JNK phosphorylation in tumor tissue. Tumor samples collected from the xenograft mice in 
(B) were analyzed by western blotting. (D) Accumulation of Bim and Bax in mitochondria. 
Mitochondrial fractionations isolated from the tumors in (B) were analyzed by western blotting. 
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Figure 3-10. Side effect on combination drug treatment 
(A) Hematoxylin and eosin staining of heart tissues. At the end of the experiment in (Fig 3-9B), 
heart ventricles were collected from the mice and analyzed by hematoxylin and eosin staining. 
Magnification, 200×. (B) Serum creatine phosphokinase activity. Blood was drawn from mice at 
the end of experiments in (Fig 3-9B) and serum creatine phosphokinase (CPK) activity was 
measured. n.s., p > 0.05. 
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Figure 3-11. Hematoxylin and eosin staining of mouse organs [44] 
At the end of the experiment shown in Fig 3-9B, mouse organs were harvested, stained with 
hematoxylin and eosin, and analyzed under a light microscope. Scale bar, 100 um 
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Conclusion 
 
This study shows a new the function of mitochondrial Hsp90s regulating the calcium-mediated 
interplay between the permeability transition pore (PTP) in mitochondria and the ryanodine 
receptor (RyR) in the endoplasmic reticulum (ER). The two calcium channels, PTP and RyR, 
are coordinated to propagate and amplify calcium signal-evoking stress responses, which 
consequently increases susceptibility to additional organelle stresses. The pathway is very active 
in cancer cells unless mitochondrial Hsp90s are elevated to suppress it, and we have therefore 
exploited this to selectively kill cancer cells in vivo in this study. The mitochondrial Hsp90s 
plays a critical regulatory role in mitochondrial stress signalling and protects the cell by 
suppressing mitochondria-initiated, calcium-mediated stress signals in cancer cells. Though the 
calcium signal has been intensively studied so far, “mitochondria-initiated” calcium cross-talk 
between mitochondria (PTP) and the ER (RyR) has not been reported before. This will be 
appreciated not only as a novel calcium signaling pathway but also as a part of the largely 
unknown retrograde signaling from the mitochondria to nucleus. The sequential events 
including in PTP opening, RyR opening, ER calcium depletion and UPRER induce CHOP 
expression and sensitize cancer cells to cell death. We provide here a rationale for combination 
cancer therapeutics development lowering the cell death threshold exclusively in cancer cells by 
targeting the coordinated calcium pathway. The importance of the novel calcium signaling was 
further proved by exploiting combination cancer therapy. We found that doxorubicin (trade 
name Adriamycin) or Thapsigargin together with mitochondrial UPR inducer, G-TPP, showed 
strong synergism through the mitochondria and ER crosstalk. The rationale can be exploited to 
find effective and better multicomponent anticancer regimen combining antitumor drugs or even 
non-antitumor drugs, and thereby to benefit the cancer patients in the future. 
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